Stock ACRV ACRIVON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Real-time Estimate Cboe BZX
Other stock markets
 19:32:33 28/05/2024 BST 		5-day change 1st Jan Change
7.795 USD -1.95% Intraday chart for Acrivon Therapeutics, Inc. -5.60% +57.52%
05-14 Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 North American Morning Briefing : More Earnings -2- DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
MT
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating
MT
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating
MT
JMP Securities Starts Acrivon Therapeutics With Market Outperform Rating, $14 Price Target
MT
Maxim Initiates Acrivon Therapeutics at Buy Rating With $24 Price Target
MT
Oppenheimer Initiates Coverage on Acrivon Therapeutics With Outperform Rating, $25 Price Target
MT
BMO Capital Initiates Acrivon Therapeutics at Outperform With $25 Price Target
MT
HC Wainwright Initiates Coverage on Acrivon Therapeutics With Buy Rating, $24 Price Target
MT
Jefferies Starts Acrivon Therapeutics at Buy With $17 Price Target
MT
Piper Sandler Starts Acrivon Therapeutics at Overweight With $25 Price Target
MT
Cowen Starts Acrivon Therapeutics at Outperform
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACRV Stock
  4. News Acrivon Therapeutics, Inc.
  5. Analyst Reco.